Sana Biotechnology
SANA
117 hedge funds and large institutions have $986M invested in Sana Biotechnology in 2022 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 26 reducing their positions, and 12 closing their positions.
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
62% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 26
11% more funds holding
Funds holding: 105 → 117 (+12)
3.92% more ownership
Funds ownership: 59.08% → 63% (+3.9%)
4% less call options, than puts
Call options by funds: $136K | Put options by funds: $141K
43% less capital invested
Capital invested by funds: $1.73B → $986M (-$741M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$29.2M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$8.64M |
| 3 |
Morgan Stanley
New York
|
+$8.53M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.84M |
| 5 |
Renaissance Technologies
New York
|
+$6.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
-$34.2M |
| 2 |
DIG
Dragoneer Investment Group
San Francisco,
California
|
-$23.2M |
| 3 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$1.87M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$1.42M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.33M |
SANA Hedge Fund Activity: Q1 2022 in Review
117 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Sana Biotechnology (SANA) for Q1 2022, worth a combined $986M — down 43% from $1.73B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new SANA positions and 12 closed out — a net gain of 12 holders — while 42 added to existing stakes and 26 trimmed.
The largest buyer was State Street, adding an estimated $29.2M. The largest seller was SB Management, exiting entirely with an estimated $34.2M sold.
- 117 institutional investors held Sana Biotechnology (SANA) as of Q1 2022, up from 105 in Q4 2021.
- Funds reported $986M of Sana Biotechnology stock for Q1 2022, down 43% quarter-over-quarter.
- 24 funds opened new Sana Biotechnology positions in Q1 2022 and 12 closed out, a net change of +12 holders.
- The largest Sana Biotechnology buyer in Q1 2022 was State Street, an estimated $29.2M added.
- The largest Sana Biotechnology seller in Q1 2022 was SB Management, an estimated $34.2M sold.
Based on aggregated 13F filings for Q1 2022.